Stanford Medicine Presents Additional Positive Data from Investigator-Sponsored Phase 1b/2a Study of Briquilimab in Patients with Fanconi Anemia
REDWOOD CITY, CA, USA I December 10, 2023 I Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation (Flu/TBI) conditioning in older adults with acute myeloid leukemia (AML) in complete remission (CR) or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). The results were presented by Dr. Arpita Gandhi, M.D., M.S., Assistant Professor of Medicine in the Division of Hematology/Medical Oncology at the Oregon Health & Science University School of Medicine during an oral session at the America Society of Hematology (ASH) 2023 Annual Meeting & Exposition, being held December 9-12, 2023 in San Diego, CA and virtually.
The study enrolled 32 adult patients (62 to 79 years) with AML in CR (n=13), MDS (n=16), or AML not in CR (n=3). Following a 0.6 mg/kg infusion of briquilimab, serum levels were assessed to determine start of Flu at 30 mg/m 2/day on Transplant Day (TD) -4, -3, -2, and TBI 2-3 Gy on TD0. Peripheral blood grafts were infused on TD0 (10-14 days after briquilimab). Primary endpoints were safety, tolerability, and briquilimab pharmacokinetics, and secondary endpoints included engraftment, chimerism, measurable residual disease (MRD) clearance, acute graft-versus-host-disease (GVHD), chronic GVHD, non-relapse mortality (NRM), regression-free survival (RFS), and overall survival (OS) at 1 year. Results from the study demonstrated that a regimen of briquilimab plus Flu/TBI led to successful engraftment of donor blood stem cell without the associated short and long-term toxicities that accompany busulfan-based regimens commonly used in transplant of donor or gene-corrected cells, and led to promising early minimum residual disease clearance. Further, briquilimab dosing resulted in predictable pharmacokinetics and allowed donor cell infusion 9-14 days after administration, and all patients who engrafted achieved neutrophil recovery before TD +26.
Also at ASH, Dr. Rajni Agarwal, Professor of Pediatrics in the Division of Stem Cell Transplantation at the Stanford Medicine presented new positive results from the investigator-sponsored Phase 1b/2a study evaluating briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA). Data from the study show that briquilimab infusion appears to be safe and well tolerated in patients with FA, that it is feasible to generate adequate hematopoietic stem cell grafts from haplo donors with resulting safe and well tolerated graft infusions, and that all patients enrolled engrafted promptly within 2 weeks of transplant with stable donor chimerism of > 95% in all lineages. The 2a portion of the study is ongoing and continues to enroll patients.
“We are pleased with the results from both studies presented at ASH, demonstrating the potential of briquilimab to serve as a crucial component of non-toxic conditioning regimens for stem cell transplant to treat AML/MDS and FA,” said Edwin Tucker, M.D., Chief Medical Officer of Jasper. “We continue to enroll patients in our Phase 1b trial evaluating briquilimab as a second-line therapy in subjects with LR-MDS and look forward to presenting data from that study next year, in addition to data from our core mast cell disease programs.”
About Briquilimab
Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven disease such as chronic urticaria. Jasper is evaluating briquilimab as a treatment in patients with Chronic Spontaneous Urticaria, and will begin clinical development in Chronic Inducible Urticaria as well. Briquilimab is also currently in clinical studies as a treatment for patients with Low to Intermediate Risk myelodysplastic syndromes (MDS) and as a conditioning agent for cell and gene therapies for rare diseases. To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), MDS, Fanconi anemia (FA), and sickle cell disease (SCD).
About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk MDS and as a conditioning agent for stem cell transplants for rare diseases such as SCD, FA and SCID. To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, AML, MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com.
SOURCE: Jasper Therapeutics
Post Views: 161
Stanford Medicine Presents Additional Positive Data from Investigator-Sponsored Phase 1b/2a Study of Briquilimab in Patients with Fanconi Anemia
REDWOOD CITY, CA, USA I December 10, 2023 I Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation (Flu/TBI) conditioning in older adults with acute myeloid leukemia (AML) in complete remission (CR) or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). The results were presented by Dr. Arpita Gandhi, M.D., M.S., Assistant Professor of Medicine in the Division of Hematology/Medical Oncology at the Oregon Health & Science University School of Medicine during an oral session at the America Society of Hematology (ASH) 2023 Annual Meeting & Exposition, being held December 9-12, 2023 in San Diego, CA and virtually.
The study enrolled 32 adult patients (62 to 79 years) with AML in CR (n=13), MDS (n=16), or AML not in CR (n=3). Following a 0.6 mg/kg infusion of briquilimab, serum levels were assessed to determine start of Flu at 30 mg/m 2/day on Transplant Day (TD) -4, -3, -2, and TBI 2-3 Gy on TD0. Peripheral blood grafts were infused on TD0 (10-14 days after briquilimab). Primary endpoints were safety, tolerability, and briquilimab pharmacokinetics, and secondary endpoints included engraftment, chimerism, measurable residual disease (MRD) clearance, acute graft-versus-host-disease (GVHD), chronic GVHD, non-relapse mortality (NRM), regression-free survival (RFS), and overall survival (OS) at 1 year. Results from the study demonstrated that a regimen of briquilimab plus Flu/TBI led to successful engraftment of donor blood stem cell without the associated short and long-term toxicities that accompany busulfan-based regimens commonly used in transplant of donor or gene-corrected cells, and led to promising early minimum residual disease clearance. Further, briquilimab dosing resulted in predictable pharmacokinetics and allowed donor cell infusion 9-14 days after administration, and all patients who engrafted achieved neutrophil recovery before TD +26.
Also at ASH, Dr. Rajni Agarwal, Professor of Pediatrics in the Division of Stem Cell Transplantation at the Stanford Medicine presented new positive results from the investigator-sponsored Phase 1b/2a study evaluating briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA). Data from the study show that briquilimab infusion appears to be safe and well tolerated in patients with FA, that it is feasible to generate adequate hematopoietic stem cell grafts from haplo donors with resulting safe and well tolerated graft infusions, and that all patients enrolled engrafted promptly within 2 weeks of transplant with stable donor chimerism of > 95% in all lineages. The 2a portion of the study is ongoing and continues to enroll patients.
“We are pleased with the results from both studies presented at ASH, demonstrating the potential of briquilimab to serve as a crucial component of non-toxic conditioning regimens for stem cell transplant to treat AML/MDS and FA,” said Edwin Tucker, M.D., Chief Medical Officer of Jasper. “We continue to enroll patients in our Phase 1b trial evaluating briquilimab as a second-line therapy in subjects with LR-MDS and look forward to presenting data from that study next year, in addition to data from our core mast cell disease programs.”
About Briquilimab
Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven disease such as chronic urticaria. Jasper is evaluating briquilimab as a treatment in patients with Chronic Spontaneous Urticaria, and will begin clinical development in Chronic Inducible Urticaria as well. Briquilimab is also currently in clinical studies as a treatment for patients with Low to Intermediate Risk myelodysplastic syndromes (MDS) and as a conditioning agent for cell and gene therapies for rare diseases. To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), MDS, Fanconi anemia (FA), and sickle cell disease (SCD).
About Jasper
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk MDS and as a conditioning agent for stem cell transplants for rare diseases such as SCD, FA and SCID. To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, AML, MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com.
SOURCE: Jasper Therapeutics
Post Views: 161
